All studies involving NZL/LtJ

Data set	Procedure	What's in this data set	Panel	Sex	Age (weeks)	Year
Broad2	genotyping	SNP profiling, 131,000+ genomic locations, 1-19,X.	inbred   (89)			2009
CGD-MDA1	genotyping	SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT.	inbred   (142)	m		2014
CGDpheno1	body size and weight	Body weight and length.	inbred w/CC8   (72)	both	10-13wks	2009
CGDpheno1	complete blood count	Hematology.	inbred w/CC8   (72)	both	10-13wks	2009
CGDpheno1	DXA	Body mass, fat mass, lean mass, bone mineral density.	inbred w/CC8   (72)	both	10-13wks	2009
CGDpheno1	lipid profile	Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma.	inbred w/CC8   (72)	both	10-13wks	2009
CGDpheno1	metabolic panel	Clinical blood chemistry (plasma). 4h fast.	inbred w/CC8   (72)	both	10-13wks	2009
Crowley1	behavior observation with haloperidol	Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints).	inbred w/CC8   (27)	m	9-28wks	2012
Crowley1	body weight with haloperidol	Baseline vs. after haloperidol 60d implant.	inbred w/CC8   (27)	m	9-28wks	2012
Crowley1	drug and metabolite quantification with haloperidol	Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints).	inbred w/CC8   (27)	m	9-28wks	2012
Crowley1	inclined screen test with haloperidol	Baseline vs. during and after haloperidol 60d implant (several timepoints).	inbred w/CC8   (27)	m	9-28wks	2012
Crowley1	open field test with haloperidol	Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test.	inbred w/CC8   (27)	m	9-28wks	2012
Gros1	genotype assessment with Candida albicans	C5 allele sufficiency or deficiency.	inbred   (36)	f	8-12wks	2011
Gros1	in vitro assay with Candida albicans	Susceptibility to infection with Candida albicans.	inbred   (36)	f	8-12wks	2011
UCLA1	genotyping	SNP profiling, 132,000+ genomic locations, 1-19,X	HMDP   (248)	both		2018